Pain Medication Questionnaire (PMQ)

Foundational Context

Chronic pain treatment often requires balancing analgesic benefit with the risks associated with prescription opioids. The PMQ was created to improve early detection of patients who may be at greater risk for medication misuse. Its item set captures known psychosocial correlates of opioid-related risk, including:

• Preoccupation with medication
• Past substance misuse
• Pain-related distress
• Inconsistent adherence
• Emotional or behavioural responses to opioid use

Unlike some risk tools based solely on clinician ratings or historical factors, the PMQ centers patient self-report to reveal attitudes and behaviors that may not appear in chart reviews. The tool supplements, rather than replaces, clinical judgment and comprehensive assessment.

What the Assessment Measures

The PMQ evaluates behavioural and psychological factors associated with opioid misuse risk:

• Concerns about access to medication
• Worry over inadequate dosing
• Tendency to self-adjust doses
• Using medication to cope emotionally
• History of substance use
• Inconsistent or maladaptive adherence behavior
• Pain-related distress and frustration

All items contribute to one summed risk score.

Interpretation Guidelines

Scores reflect the overall level of opioid misuse risk factors:

• Range: 26–130
• Higher scores → higher risk
• Common research-supported threshold:
• ≥30–33 associated with elevated risk for aberrant medication-related behaviors

Interpretation Notes:

• No diagnostic function, scores indicate risk, not confirmed misuse
• Thresholds vary across populations and settings
• Should be integrated with broader assessments, including:
• Clinical interviews
• Prescription monitoring programs
• Collateral information
• Pain/function measures
• Elevated scores warrant closer monitoring, structured opioid agreements, or alternative pain-management planning

Psychometric Properties

Reliability

• Good internal consistency across the 26 items
• Stable factor structure related to psychosocial risk dimensions

Validity

• Predictive validity demonstrated for aberrant medication behaviors
• Correlates with clinician-observed risk indicators
• Good sensitivity for high-risk populations
• Not validated as a diagnostic measure for substance use disorders

Administration Considerations

• Straightforward self-report, easy to administer in clinical settings
• Must be interpreted within a harm-reduction and non-stigmatizing framework
• Elevated scores do not imply noncompliance or wrongdoing, risk factors are multifactorial
• Should not influence prescribing decisions without corroborating assessment
• Useful as part of multidisciplinary pain management

Limitations

• Risk assessment only, does not detect actual misuse
• Self-report may be influenced by stigma or fear of medication restriction
• Some items overlap with legitimate concerns of chronic pain patients
• Cultural and contextual factors may influence responses
• Should not be used in isolation to deny treatment or determine culpability

Pain Medication Questionnaire (PMQ) Overview

Validated 26-item self-report screen for opioid misuse risk in chronic pain patients. Used before initiating or continuing long-term opioid therapy.

26 items × 0–4 scale. Total score range: 0–104. Cutoff ≥23 = elevated risk.

Important: PMQ scores are risk indicators, not prescribing mandates. A score ≥23 warrants enhanced monitoring, it does not justify withholding pain treatment. Use in conjunction with PDMP review, clinical interview, and urine drug screening as part of a thorough risk management approach.

PMQ vs ORT vs SOAPP-R

Three validated opioid misuse risk screeners, each with different trade-offs.

Recommended approach: No single screener is sufficient alone. Many pain programs use the ORT for rapid initial triage and the PMQ or SOAPP-R for detailed pre-prescribing evaluation. Using two tools with different methodologies (clinician vs self-report) reduces response bias and improves overall risk stratification accuracy.

Documenting PMQ Results in Clinical Notes

Record the PMQ total score, risk category, and any elevated domain scores in the Objective section. Document the clinical response to elevated risk (e.g., enhanced monitoring plan, PDMP review date).

Frequently Asked Questions

What is the PMQ scoring cutoff?

The Pain Medication Questionnaire (PMQ) has 26 items each scored 0–4, giving a total range of 0–104. The validated clinical cutoff is ≥23: Adams et al. (2004) found that a score of 23 or above was associated with significantly elevated risk for opioid medication misuse in chronic pain patients. Scores below 23 suggest lower risk, though clinical judgment should always guide prescribing decisions.

What does the PMQ measure?

The PMQ screens for opioid medication misuse risk across four domains: (1) Attitude toward medication, beliefs about the necessity and appropriateness of pain medications; (2) Social support, availability of supportive relationships that buffer against misuse; (3) History, prior substance use, legal issues, or treatment noncompliance; (4) Compliance, adherence to prescribed treatment regimens. Together these factors assess the likelihood that a chronic pain patient will misuse prescribed opioids.

When should the PMQ be administered?

The PMQ is typically administered before initiating long-term opioid therapy for chronic pain, as part of a pre-prescribing risk assessment. It is also used at regular intervals during ongoing opioid treatment to monitor for emerging risk factors. Many pain clinics administer the PMQ alongside the SOAPP-R (Screener and Opioid Assessment for Patients with Pain) or ORT (Opioid Risk Tool) as a multi-source risk stratification battery.

How is the PMQ different from the ORT and SOAPP-R?

The PMQ, ORT (Opioid Risk Tool), and SOAPP-R are all opioid misuse risk screeners used in chronic pain settings. The ORT is a brief 5-item clinician-administered tool categorizing risk as low, moderate, or high. The SOAPP-R is a 24-item patient self-report tool. The PMQ is a 26-item self-report with the most extensive validation across chronic pain populations (Adams et al., 2004). Many pain clinics use more than one tool because no single screener has sufficient sensitivity/specificity on its own to make prescribing decisions.

Is a high PMQ score a reason to refuse opioid therapy?

No. A PMQ score ≥23 is a risk signal that warrants enhanced monitoring, not automatic exclusion from treatment. Guidelines from the CDC and pain specialty organizations recommend using screeners to guide the level of monitoring and support, not as gatekeeping tools. A high-risk patient may need more frequent check-ins, urine drug screening, prescription drug monitoring program (PDMP) review, or co-management with addiction medicine, not denial of pain treatment.

Is the PMQ validated for different chronic pain conditions?

The PMQ was originally validated in heterogeneous chronic pain outpatient populations including back pain, neuropathic pain, and fibromyalgia. Subsequent studies have validated it across spine surgery, headache, and multidisciplinary pain program populations. It performs consistently across pain types, making it a generalizable screening tool for any clinical setting prescribing long-term opioids.